Leann Silhan
Pulmonary Disease · Dallas, TXNPI 1952436172
Payments from drug & device makers
Across 39 payments — averaging $1280.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$48K
- Genentech, Inc.$1K
- AbbVie$92
- Cleerly, Inc.$57
- Exact Sciences$56
- GSK$39
- plus $356 from 15 others
What the payments were for
- Grants$1,00061%
- Food & beverage$63539%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $48,357 |
| Genentech, Inc. | 1 | $1,000 |
| AbbVie | 5 | $92 |
| Cleerly, Inc. | 1 | $57 |
| Exact Sciences | 3 | $56 |
| GSK | 2 | $39 |
| Novo Nordisk | 2 | $37 |
| Pfizer | 2 | $35 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Antares Pharma, Inc. | 2 | $32 |
| Genentech USA, Inc. | 3 | $32 |
| Merck | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Perspectum Diagnostics Ltd | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Echosens North America, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Halozyme Inc | 1 | $13 |
How this compares
$49,956 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $243,565 |
| OfevNintedanib Esylate | 11 | $140,792 |
| CreonLipase/Protease/Amylase | 14 | $16,780 |
| EliquisApixaban | 16 | $11,831 |
| Tadalafil | 12 | $8,214 |
| DayvigoLemborexant | 11 | $5,718 |
| Enoxaparin Sodium | 12 | $3,369 |
| Doxycycline Hyclate | 11 | $398 |
| Gabapentin | 14 | $339 |
| Mirtazapine | 25 | $295 |
| Metformin Hcl | 12 | $253 |
| Losartan Potassium | 30 | $227 |
| Bupropion XlBupropion Hcl | 15 | $191 |
| Rosuvastatin Calcium | 21 | $166 |
| Atorvastatin Calcium | 15 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $21 | $243,56513 claims |
| Boehringer IngelheimOfev | $48,357 | $140,79211 claims |
| AbbVieCreon | $92 | $16,78014 claims |
| PfizerEliquis | $35 | $11,83116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Dallas
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Trushil ShahDallas$1.4M
- Yolanda MagetoDallas$1.4M
- Mark MillardDallas$1.2M
- Chetan NaikDallas$678K
- Craig GlazerDallas$469K
- Yosafe WakwayaDallas$439K
- Sonja BartolomeDallas$423K
- Corey KershawDallas$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.